These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 35431535)

  • 61. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
    Li Q; Wang J; Tang Y; Lu H
    Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
    [TBL] [Abstract][Full Text] [Related]  

  • 62. SARS-CoV-2 Variants of Concern.
    Choi JY; Smith DM
    Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
    Duan LJ; Jiang WG; Wang ZY; Yao L; Zhu KL; Meng QC; Wang BS; Li LB; Wang GL; Ma MJ
    iScience; 2022 Sep; 25(9):104886. PubMed ID: 35966041
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic.
    Rahman S; Hossain MJ; Nahar Z; Shahriar M; Bhuiyan MA; Islam MR
    Environ Health Insights; 2022; 16():11786302221129396. PubMed ID: 36299441
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.
    He X; He C; Hong W; Yang J; Wei X
    Med Res Rev; 2023 Jul; 43(4):932-971. PubMed ID: 36929527
    [TBL] [Abstract][Full Text] [Related]  

  • 66. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
    Martínez-Flores D; Zepeda-Cervantes J; Cruz-Reséndiz A; Aguirre-Sampieri S; Sampieri A; Vaca L
    Front Immunol; 2021; 12():701501. PubMed ID: 34322129
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants.
    Chaki SP; Kahl-McDonagh MM; Neuman BW; Zuelke KA
    Microbiol Spectr; 2022 Jun; 10(3):e0066522. PubMed ID: 35638906
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
    Ikegame S; Siddiquey MNA; Hung CT; Haas G; Brambilla L; Oguntuyo KY; Kowdle S; Chiu HP; Stevens CS; Vilardo AE; Edelstein A; Perandones C; Kamil JP; Lee B
    Nat Commun; 2021 Jul; 12(1):4598. PubMed ID: 34312390
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
    Front Immunol; 2020; 11():1880. PubMed ID: 32973779
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
    van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
    mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic.
    Noor R
    Bull Natl Res Cent; 2022; 46(1):31. PubMed ID: 35194369
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
    Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
    Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 75. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
    Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981056
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
    Jia Z; Gong W
    J Korean Med Sci; 2021 May; 36(18):e124. PubMed ID: 33975397
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
    Kumari M; Lu RM; Li MC; Huang JL; Hsu FF; Ko SH; Ke FY; Su SC; Liang KH; Yuan JP; Chiang HL; Sun CP; Lee IJ; Li WS; Hsieh HP; Tao MH; Wu HC
    J Biomed Sci; 2022 Sep; 29(1):68. PubMed ID: 36096815
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic.
    Chadha J; Khullar L; Mittal N
    Environ Microbiol; 2022 Jun; 24(6):2615-2629. PubMed ID: 34320263
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development of SARS-CoV-2 Vaccine: Challenges and Prospects.
    Mahboob T; Ismail AA; Shah MR; Rahmatullah M; Paul AK; Pereira ML; Wiart C; Wilairatana P; Rajagopal M; Dolma KG; Nissapatorn V
    Diseases; 2023 Apr; 11(2):. PubMed ID: 37092446
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021.
    Wu D; Zhang Y; Tang L; Wang F; Ye Y; Ma C; Zheng H; Yu W; Cao L; Song Y; Reyimu A; Zhang X; Wang H; Nie Y; Lu M; Qi M; Li J; Wang R; Yang K; Wang C; Rodewald LE; Gao GF; An Z; Yin Z
    China CDC Wkly; 2022 Jan; 4(4):57-65. PubMed ID: 35186369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.